News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Morphotek Inc. Announces License Agreement for the Development of a Monoclonal Antibody to Treat Prostate Cancer


8/13/2008 8:43:16 AM

EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced today that it has signed a license agreement with the National Cancer Institute (NCI) for the rights to a monoclonal antibody for a novel antigen identified by NCI researchers. Morphotek will apply its proprietary MORPHODOMA® antibody technology to the development of novel human therapeutic antibodies for use in the treatment of prostate cancer.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES